** Shares of biopharma co Halozyme Therapeutics HALO.O fall 4.5% to $47.98
** Morgan Stanley downgrades HALO's rating to "equal-weight" from "overweight"; cuts PT to $62 from $73
** The U.S. Centers for Medicare and Medicaid Services $(CMS)$ draft may impact HALO's drug pricing, posing a headwind for hyaluronidase products, brokerage says
** CMS said on Monday it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year
** HALO utilizes hyaluronidase enzymes to develop injectable versions of various drugs
** Brokerage says the draft guidance could sway industry incentives and pose a meaningful headwind for hyaluronidase combination products for HALO
** Halozyme has risen ~5% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。